SENP3 releases SUMO2 and SUMO3 monomers from sumoylated substrates, but has only weak activity against SUMO1 conjugates. This protein deconjugates SUMO2 from MEF2D, which increases its transcriptional activation capability.
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Target:
The synthetic peptide sequence used to generate the antibody AP1235a was selected from the C-term region of human SENP3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
* VAT and and shipping costs not included. Errors and price changes excepted
